FDA authorizes Novavax's COVID-19 vaccine for teens

The Food and Drug Administration on Friday cleared Novavax’s coronavirus vaccine for emergency use in children 12 to 17 years old, giving adolescents a third option to prevent COVID-19 as they return to school. The agency’s decision comes a month after the FDA authorized the shot for adults and more than a year after teenagers became eligible for the messenger RNA shots from Pfizer and, later, Moderna. The Centers for Disease Control and Prevention signed off on the FDA’s decision Monday.